Biotechnology

IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy

January 8, 2025 8:30 AM

POTOMAC, MD / ACCESSWIRE / January 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced today that its ongoing Phase 2 trial for agitation in Alzheimer's disease has been officially named CALMA (Calming Agitation in Alzheimer's). The trial's new identity reflects its mission to address agitation, a syndrome affecting up to 76% of the 55 million Alzheimer's patients worldwide that also adversely impacts the...

Read more

Bionoid Pharma, Inc. Reports Over $100,000 in Revenue Following Binding LOI With Your Supplement Supply Store Ltd.

January 8, 2025 7:30 AM

Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) is pleased to announce the generation of over $100,000 in revenue following the signing of a Binding Letter of Intent (LOI) with Your Supplement Supply Store Ltd. This significant milestone underscores the strategic value of the agreement and demonstrates the potential of Bionoid's growth strategy. The LOI with Your Supplement Supply Store Ltd. represents a pivotal step in Bionoid's expansion into...

Read more

BioInvent Announces Promising Initial Efficacy Data from Triple Combination Arm of BI-1206, Rituximab and Calquence for the Treatment of non-Hodgkin's Lymphoma

January 8, 2025 2:20 AM

LUND, SWEDEN / ACCESSWIRE / January 8, 2025 / BioInvent International (STO:BINV) The first two patients enrolled in the Phase 2a study triplet arm combining BI-1206 with rituximab and Calquence® responded to treatment One complete response (CR) and one partial response (PR) The treatment has been well-tolerated with no safety or tolerability concerns Study now expanding to additional clinical investigational sites and patient enrollment on track...

Read more

BioInvent Announces Promising Data for BI-1910 as Single Agent from Phase 1 Study in Solid Tumors

January 8, 2025 2:20 AM

LUND, SWEDEN / ACCESSWIRE / January 8, 2025 / BioInvent International (STO:BINV) BI-1910 single agent Phase 1 Part A dose escalation has been completed and reached a biologically active dose level. Data show stable disease as best clinical response with no notable adverse events even at the highest doses tested. Phase 1 part B evaluating BI-1910 in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) initiated BioInvent is...

Read more

Lifeloc Technologies Secures $750,000 Financing to Support Growth and Innovation

January 7, 2025 4:38 PM

Lifeloc Technologies, Inc. (OTC PINK:LCTC), a leading provider of portable breath alcohol testing devices and related solutions, today announced the successful closing of a $750,000 financing transaction through a subordinated debenture agreement with Diamond Bridge Capital, LP. The financing also includes a warrant granting Diamond Bridge Capital the right to purchase up to 62,500 shares of Lifeloc's common stock at a strike price of $4.50 per...

Read more

Next Gen Diagnostics and Sheba Medical Center Announce Agreement for NGD to Sequence and Analyze Unique Collection of Highly Resistant Bacterial Infections

January 7, 2025 11:00 AM

CAMBRIDGE, MA and RAMAT GAN, ISRAEL / ACCESSWIRE / January 7, 2025 / Next Gen Diagnostics (NGD), a world leader in the development of validated machine learning models for whole genome sequence- (WGS-) based detection of transmission and for the determination of bacterial susceptibility to antibiotics, and Sheba Medical Center, the largest medical complex in Israel and the Middle East, announce an agreement providing for the sequencing and...

Read more

ProteinQure Strengthens Leadership Team with Key Appointments to Accelerate Translational and Clinical Development Programs

January 7, 2025 10:45 AM

ProteinQure, a leader in computational peptide design, is proud to announce the addition of two distinguished leaders to its team. Dr. Dave Garman has been appointed as Vice President of Translation and Development, and Dr. Edward Garmey has joined as consulting Chief Medical Officer. These strategic hires strengthen ProteinQure's ability to advance its clinical asset PQ203 and additional programs in their pipeline. PQ203 is a first-in-class...

Read more

Petros Pharmaceuticals Strategically Positioned to Benefit as Technology Leader from Newly Approved FDA OTC Final Rules

January 7, 2025 9:15 AM

Proprietary technology developing quantum computing and applying AI to better enable Rx to OTC switch candidates across multiple indications NEW YORK, NY / ACCESSWIRE / January 7, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, today announces its conducive position in connection with the...

Read more

Adnexus Biotechnologies Inc. Unveils AI-Driven Malaria Cure with Trapicolast

January 7, 2025 7:00 AM

Adnexus Biotechnologies Inc. proudly announces the launch of Trapicolast, a pioneering antimalarial drug developed through its innovative AI-powered Sutra™ platform. Integrating AI Platform discovered ADX1 and ADX2, this breakthrough medication targets dual mechanisms within the Plasmodium parasite, attacking both the apicoplast and vesicular trafficking pathways. A New Era in Malaria Treatment Traditional antimalarial treatments have primarily...

Read more

GlyTherix and 3D Imaging Establish Strategic Alliance for Radiopharmaceutical Development and Manufacturing in the U.S.

January 3, 2025 7:45 AM

SYDNEY, AUSTRALIA and LITTLE ROCK, AR / ACCESSWIRE / January 3, 2025 / GlyTherix Ltd (GlyTherix), an Australian targeted radiotherapy company, and 3D Imaging LLC (3DI), a Contract Development and Manufacturing Organization (CDMO) specializing in radiopharmaceuticals, are pleased to announce the execution of a Master Service Agreement. This collaboration combines 3DI's cutting-edge radiopharmaceutical manufacturing expertise with GlyTherix's...

Read more

IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025

December 19, 2024 7:00 PM

POTOMAC, MD / ACCESSWIRE / December 19, 2024 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced that the Company's management team will participate in BIO Partnering @ JPM, scheduled alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025. Management will be available for in-person and virtual meetings. Details of the events are as follows: Event: BIO Partnering @ JPM Date: January 13 - 16, 2025...

Read more

PetVivo Holdings, Inc. Announces Participation in The Microcap Conference 2025

December 19, 2024 1:45 PM

MINNEAPOLIS, MN / ACCESSWIRE / December 19, 2024 / PetVivo Holdings, Inc. (OTCQB:PETV, PETVW), a leading provider of medical devices and biomedical therapeutics for equines and companion animals, is pleased to announce its participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ. John Lai,...

Read more

IPA to Present at The Microcap Conference 2025

December 19, 2024 10:15 AM

VICTORIA, BC / ACCESSWIRE / December 19, 2024 / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today announced is pleased to announce its participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, in Atlantic City, NJ. IPA's management team will deliver a...

Read more

Petros Pharmaceuticals Featured in “New Era of Healthcare, AI, Data and Consumer Empowerment”

December 19, 2024 9:15 AM

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today announced that in a recent podcast, The Intelligent Leadership Podcast, titled, "The New Era of Healthcare, AI, Data and Consumer Empowerment," Petros President Fady Boctor discussed the Company's concerted efforts to develop its proprietary platform...

Read more

Gene Guard Detox, Inc. Seeks Strategic Investors to Transform Newly Patented Toxin-Removal Science for Glyphosate & BPA Into Commercialization

December 19, 2024 9:00 AM

Gene Guard Detox, Inc., an innovative health and wellness company, is seeking strategic investment partners to commercialize its patented probiotics and postbiotics. Since its founding in 2019, the company has developed transformative solutions to address toxins such as glyphosate and BPA in humans and pets. Through proprietary research, Gene Guard Detox has demonstrated remarkable toxin-binding capabilities of its probiotic strains, including:...

Read more

Michael L. Baum, Esq. Renowned Advocate Added to Board of Gene Guard Detox, Inc.

December 18, 2024 9:00 AM

Gene Guard Detox, Inc. proudly welcomes Michael L. Baum, Esq. to its Board of Directors. An award-winning litigator and champion for victims of Drugs as well as glyphosate exposure, Baum has set new standards in environmental and health-related justice. Baum's exceptional legal career includes: Wisner Baum HPV vaccine attorneys are bringing the first Gardasil lawsuit to trial on January 21, 2025, in California State Court. Trial Team for the Lee...

Read more

Osceola County Commission Approves Negotiations With Medical Device Company to Establish Presence at NeoCity

December 17, 2024 4:30 PM

The Osceola County Board of County Commissioners has approved a Memorandum of Understanding (MOU) with Concept Companies and Empyrean Medical Systems, Inc., a global medical device technology company, marking another significant step in developing NeoCity as a premier technological innovation district. Under Monday's MOU, Empyrean would consider leasing space at NeoCity in 2025, focusing on advanced engineering and precision parts fabrication...

Read more

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

December 17, 2024 9:15 AM

FRAMINGHAM, MA / ACCESSWIRE / December 17, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced that announced that Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic participated in a Virtual Investor "What This Means" segment As part of...

Read more

Proprietary Technology Addressing the Rx-to-OTC Switch Self-Care Market Valued at over $38 Billion annually

December 17, 2024 9:00 AM

Working to identify quantum computing partnerships to strengthen our AI technology to include critical health records to better enable Rx to OTC switch candidates across multiple indications NEW YORK, NY / ACCESSWIRE / December 17, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today announces a...

Read more

Adnexus Biotechnologies Unveils Neural Temporal Fingerprinting for Personalized Health Monitoring Using Artificial Intelligence

December 17, 2024 7:00 AM

Adnexus Biotechnologies Inc. is proud to announce the launch of AI-Driven Neural Temporal Fingerprinting, a groundbreaking technology designed to predict and monitor neurological and cardiovascular conditions with unparalleled accuracy. This innovation is developed under the umbrella of the company's advanced AI platform, Sutra. The brain and heart of each person send signals with patterns of long and short signals, and EEG and ECG read these...

Read more